GRIA2 Gene

GRIA2 Gene

Introduction

GRIA2 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GRIA2 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GRIA2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Glutamate Ionotropic Receptor AMPA Type Subunit 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>4q32.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2892</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>138247</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000120251</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P42263</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Glutamate receptor 2 (GluA2)</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Ionotropic glutamate receptor (AMPA type)</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Cerebral [cortex](/brain-regions/cortex)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Striatum](/brain-regions/striatum)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Thalamus](/brain-regions/thalamus)</td>
<td>Moderate-high</td>
</tr>
<tr>
<td class="label">[Cerebellum](/brain-regions/cerebellum)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Low-moderate</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/cardiovascular" style="color:#ef9a9a">Cardiovascular</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">53 edges</a></td>
</tr>
</table>

The GRIA2 gene encodes the GluA2 subunit of the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor, one of the most critical ionotropic glutamate receptors in the central nervous system. The GluA2 subunit is unique among AMPA receptor subunits because it undergoes RNA editing at the Q/R site, which fundamentally alters the channel's biophysical properties and renders the receptor calcium-impermeable. This editing is essential for normal neuronal function, and deficiencies in GRIA2 editing have been strongly implicated in amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), epilepsy, and various neurodevelopmental disorders["@hideyama2018"][@liu2019].

The GRIA2 gene is located on chromosome 4q32.1 and is alternatively spliced to produce multiple isoforms that differ in their C-terminal intracellular domains. These isoforms regulate receptor trafficking, synaptic anchoring, and downstream signaling through interactions with various PDZ domain-containing proteins. Understanding the molecular mechanisms by which GRIA2 influences neuronal survival and function is critical for developing therapeutic strategies targeting excitotoxicity and synaptic dysfunction in neurodegenerative diseases["@slotkin2020"][@salpietro2021].

Gene Overview

Protein Structure and Function

Molecular Architecture

The GluA2 protein is composed of approximately 883 amino acids and adopts a classic ligand-gated ion channel architecture consisting of four distinct domains:

The Q/R RNA editing site is located in the pore-forming M2 transmembrane helix at position 607, where a glutamine (Q) codon is converted to an arginine (R) codon by adenosine deamination. This single amino acid change dramatically reduces calcium permeability through the channel[@tak Yamada2019].

RNA Editing Mechanism

The Q/R site editing of GRIA2 is catalyzed by ADAR2 (adenosine deaminase acting on RNA 2), an enzyme that recognizes a specific double-stranded RNA structure formed by the exon and intron sequences surrounding the editing site. The editing reaction converts adenosine to inosine, which is read as guanosine during translation, resulting in the Q→R amino acid substitution[@borgesius2021].

The biological significance of this editing is profound:

• Unedited GRIA2 (Q at position 607): Forms calcium-permeable AMPA receptors
• Edited GRIA2 (R at position 607): Forms calcium-impermeable AMPA receptors

Role in Synaptic Plasticity

Long-Term Potentiation and Depression

GluA2-containing AMPA receptors are essential for both long-term potentiation (LTP) and long-term depression (LTD) at CA3-CA1 hippocampal synapses. The trafficking of GluA2-containing receptors into and out of the synapse underlies the changes in synaptic strength that underlie learning and memory[@mendez2023].

LTP induction requires recruitment of calcium-permeable AMPA receptors (containing unedited GluA2 or GluA1) to the synapse, where calcium influx through these receptors activates CaMKII and downstream signaling cascades that enhance synaptic strength. However, the subsequent stabilization of LTP involves replacement with calcium-impermeable GluA2-containing receptors.

LTD induction involves internalization of GluA2-containing receptors, a process regulated by GRIP1/2 (glutamate receptor-interacting protein) and PICK1 (protein interacting with C kinase 1) PDZ domain proteins. The dynamic regulation of GluA2-containing receptor surface expression provides a molecular mechanism for bidirectional synaptic plasticity[@stanton2023].

Receptor Trafficking

GluA2 subunits contain several trafficking motifs that regulate their subcellular distribution:

• The C-terminal PDZ-binding motif (SVKI) interacts with GRIP1, GRIP2, and PICK1
• The YxxΦ endocytosis motif mediates constitutive and activity-dependent internalization
• The L/FxxxL/F motif in the C-terminus regulates synaptic retention

Disease Associations

Alzheimer's Disease

Alzheimer's disease is associated with multiple alterations in GRIA2 expression, editing, and trafficking that contribute to synaptic dysfunction and cognitive decline[@liu2019][@choi2024]:

Expression alterations: Post-mortem studies of AD brain tissue reveal significantly reduced GRIA2 mRNA and protein expression in the hippocampus and cortex, regions critically involved in learning and memory. This reduction correlates with the severity of cognitive impairment and precedes overt neuronal loss.

Trafficking dysfunction: Amyloid-beta (Aβ) oligomers directly interfere with GluA2 trafficking by:

• Disrupting the interaction between GluA2 and GRIP1 scaffolding proteins
• Enhancing AMPA receptor internalization through activation of internalization pathways
• Reducing synaptic GluA2 surface expression and synaptic current

The combination of reduced GRIA2 expression, impaired trafficking, and incomplete RNA editing creates a "perfect storm" of synaptic dysfunction in AD, making GRIA2 a promising therapeutic target[@kumar2023].

Amyotrophic Lateral SALS

GRIA2 RNA editing deficiency is one of the most consistent molecular alterations in ALS, particularly in sporadic cases[@hideyama2018][@gray2022]:

ADAR2 dysfunction: ALS is associated with reduced ADAR2 expression and activity in motor neurons. This leads to incomplete editing of the GRIA2 Q/R site, resulting in calcium-permeable AMPA receptors.

Excitotoxicity: Calcium-permeable AMPA receptors allow excessive calcium influx during glutamatergic neurotransmission. Motor neurons are particularly vulnerable to excitotoxicity due to their high metabolic demands and relatively limited calcium-buffering capacity.

Therapeutic implications: Restoring proper GRIA2 editing or blocking calcium-permeable AMPA receptors represents a promising therapeutic strategy for ALS. Several approaches are under investigation[@johnson2024][@williams2023]:

• Small molecules that enhance ADAR2 activity
• Antisense oligonucleotides targeting unedited GRIA2
• Selective antagonists of calcium-permeable AMPA receptors

Epilepsy

Reduced GRIA2 Q/R editing causes neuronal hyperexcitability and seizures[@tak Yamada2019]:

• Unedited GRIA2 leads to excessive calcium influx during excitatory neurotransmission
• This calcium influx activates pro-epileptogenic signaling cascades
• Mouse models withunedited GRIA2 develop spontaneous seizures

Neurodevelopmental Disorders

De novo variants in GRIA2 cause intellectual disability with or without epilepsy, expanding the phenotype of GRIA2-related disorders[@salpietro2021]:

• Missense variants affecting the ligand-binding domain disrupt receptor function
• Variants affecting the C-terminal domain impair receptor trafficking
• Variant carriers show developmental delay, intellectual disability, and frequently seizures

Expression Pattern

Regional Distribution

GRIA2 shows high expression throughout the forebrain:

The widespread expression of GRIA2 throughout the forebrain explains why its dysfunction affects multiple cognitive and motor systems.

Cell-Type Specificity

GRIA2 is expressed in both excitatory glutamatergic neurons and inhibitory GABAergic neurons. However, the vast majority of AMPA receptors in the adult brain contain GluA2 subunits, making this subunit essential for normal excitatory neurotransmission throughout the CNS.

Therapeutic Targets

AMPAkines

AMPAkines are positive allosteric modulators of AMPA receptors that enhance receptor activity without activating the receptor directly. By potentiating GluA2-containing receptors, AMPAkines can enhance synaptic transmission and plasticity. Several compounds have been investigated for cognitive enhancement in AD and other neurodegenerative conditions[@cimarosti2022]:

• CX516: Shown to enhance memory in clinical trials
• CX717: Investigated for ALS and cognitive disorders
• LY451395: Tested for neuroprotective effects

RNA Editing Enhancement

Restoring proper GRIA2 editing represents a targeted approach for treating excitotoxicity in ALS and AD[@martinez2022][@johnson2024]:

• ADAR2 activators: Small molecules that enhance ADAR2 catalytic activity
• Gene therapy: Viral vector delivery of ADAR2
• CRISPR editing: Base-editing approaches to introduce the R codon directly

Receptor Antagonists

Selective antagonists of calcium-permeable AMPA receptors could protect motor neurons in ALS without impairing normal glutamatergic transmission through calcium-impermeable receptors.

Animal Models

Knockout Mice

Gria2 knockout mice are embryonic lethal, demonstrating the essential role of GluA2 in development. However, conditional knockout strategies have revealed important insights:

• Motor neuron-specific knockout: Leads to age-dependent motor neuron degeneration
• Hippocampal knockout: Impairs LTP and LTD, causing learning deficits

Transgenic Models

Human GRIA2 transgenic mice expressing wild-type or edited forms of GRIA2 have been used to study:

• RNA editing dynamics
• Therapeutic interventions
• Disease mechanisms

Knock-in Models

Gria2 Q/R site knock-in mice expressing unedited (Q) or edited (R) versions allow dissection of the functional consequences of RNA editing status.

Research Directions

Current Areas of Investigation

Emerging Technologies

• CRISPR base editing: Direct correction of RNA editing sites
• Single-cell transcriptomics: Cell-type-specific understanding of GRIA2 dysregulation
• iPSC models: Patient-derived neurons for drug screening

Summary

The GRIA2 gene encodes the GluA2 AMPA receptor subunit, a critical regulator of synaptic function and neuronal survival. The Q/R RNA editing that defines GluA2's unique properties is essential for preventing excitotoxicity, and dysregulation of this process contributes to multiple neurodegenerative and neurodevelopmental disorders. Understanding and targeting GRIA2 dysfunction offers promising therapeutic strategies for conditions including Alzheimer's disease, ALS, and epilepsy.

See Also

• [AMPA Receptors](/proteins/ampa-receptors)
• [ADAR Gene](/genes/adar)
• [Excitotoxicity](/mechanisms/excitotoxicity)
• [Long-Term Potentiation](/mechanisms/long-term-potentiation)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)

References

External Links

• [NCBI Gene: GRIA2](https://www.ncbi.nlm.nih.gov/gene/2892)
• [UniProt: P42263](https://www.uniprot.org/uniprot/P42263)
• [OMIM: 138247](https://www.omim.org/entry/138247)
• [Ensembl: GRIA2](https://www.ensembl.org/Homo_sapiens/ENSG00000120251)
• [Allen Brain Atlas: GRIA2 Expression](https://human.brain-map.org/microarray/search/show?search_term=GRIA2)

Pathway Diagram

The following diagram shows the key molecular relationships involving GRIA2 Gene discovered through SciDEX knowledge graph analysis: